Latest news with #Piper Sandler
Globe and Mail
3 days ago
- Business
- Globe and Mail
Piper Sandler Sticks to Their Hold Rating for Oscar Health (OSCR)
Piper Sandler analyst Jessica Tassan maintained a Hold rating on Oscar Health yesterday and set a price target of $13.00. The company's shares closed yesterday at $14.93. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. According to TipRanks, Tassan is an analyst with an average return of -6.8% and a 36.08% success rate. Tassan covers the Healthcare sector, focusing on stocks such as Oscar Health, Omnicell, and UnitedHealth. In addition to Piper Sandler, Oscar Health also received a Hold from TR | OpenAI – 4o's Soren Coverra in a report issued on August 8. However, yesterday, Wells Fargo maintained a Sell rating on Oscar Health (NYSE: OSCR). Based on Oscar Health's latest earnings release for the quarter ending March 31, the company reported a quarterly revenue of $3.05 billion and a net profit of $275.27 million. In comparison, last year the company earned a revenue of $2.14 billion and had a net profit of $177.37 million Based on the recent corporate insider activity of 49 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of OSCR in relation to earlier this year.
Yahoo
02-08-2025
- Business
- Yahoo
Immunitybio (IBRX) Targets $80 Million Capital Raise for Business Operations
ImmunityBio, Inc. (NASDAQ:IBRX) is one of the penny stocks that will skyrocket. On July 25, the company confirmed it is eyeing $80 million in gross proceeds on the execution of a securities purchase agreement as part of a registered direct offering. It also plans to issue common stock and warrants for the purchase of additional shares. M. A. Arkhipov/ Once fully exercised, the warrants could yield up to $96 million in gross proceeds. Piper Sandler and Co. is acting as the placement agent of the registered direct offering. The net proceeds from the offering are expected to provide the company with much-needed working capital and support for its ongoing business operations. The direct offering comes on the company's ANKTIVA product, receiving FDA approval as an immunotherapy for non-muscle invasive bladder cancer. The flagship product is designated for FDA Breakthrough Therapy. ImmunityBio, Inc. (NASDAQ:IBRX) is a biotechnology company focused on developing next-generation immunotherapies and vaccines that harness the power of the immune system to fight cancer and infectious diseases. It seeks to create durable and safe protection against diseases by developing innovative therapies and cell therapies that bolster the natural immune response. While we acknowledge the potential of IBRX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: and 11 Defensive Stocks Billionaires are Buying amid US Trade Tariff Uncertainty. Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
27-07-2025
- Business
- Yahoo
Corcept Therapeutics Advances Pipeline Fueling Growth With Controlled Risk
Corcept Therapeutics Incorporated (NASDAQ:CORT) is one of the . The company completes a key drug study and has submitted a new drug application to the U.S. FDA. A biologist in a lab coat studying a culture of cells to find a cure for metabolic disorders. Corcept Therapeutics Incorporated (NASDAQ:CORT) is a California-based company specializing in cortisol modulation through glucocorticoid receptor antagonists. The company's flagship drug, Korlym®, treats Cushing's syndrome and features a growing pipeline of over 30 clinical-stage compounds targeting endocrinology, oncology, metabolism, and neurology. Corcept Therapeutics Incorporated (NASDAQ:CORT) announced the completion of its Phase 1 study involving the examination of the effects of itraconazole on the pharmacokinetics and safety of dazucorilant in healthy adults. The trial involved single-dose dazucorilant and repeated itraconazole doses. The study ran from May 31, 2024, to June 29, 2025, and is now concluded. The findings are expected to optimize drug interaction safety. Additionally, after gaining positive results from the Phase 3 ROSELLA trial and earlier Phase 2 studies, Corcept Therapeutics Incorporated (NASDAQ:CORT) has submitted a new drug application to the U.S. FDA for relacorilant. The data from the earlier studies indicated that relacorilant combined with nab-paclitaxel highly improves progression-free and overall survival compared to nab-paclitaxel alone. Analysts, including Piper Sandler and H.C. Wainwright, are maintaining their Buy rating on the stock, with a price target of $131 and $145, respectively. In addition to the rating, Corcept Therapeutics Incorporated (NASDAQ:CORT) increases its appeal by offering a rare low-risk, high-growth appeal, with a beta of 0.20 and projected EPS growth of 69.48%. While we acknowledge the potential of CORT as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 10 Metal Stocks with Insider Buying in 2025 and 10 Energy Stocks with Insider Buying in 2025 Disclosure. None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
19-07-2025
- Business
- Yahoo
Precision Drilling Gets a Lift: Piper Sandler Sees 40% Upside
Precision Drilling Corporation (NYSE:PDS) is one of the best oil drilling stocks according to Hedge Funds, especially after a fresh boost from Wall Street. On July 15, Piper Sandler initiated coverage on the stock with an Overweight rating and a $72 price target, signaling over 40% upside from current levels. The firm highlighted Precision's operational efficiency and disciplined cost structure, noting its strong position even as the U.S. land drilling market cools under falling rig counts and commodity price pressure. The timing of this call is notable. Precision (NYSE:PDS) just wrapped up a solid first quarter, delivering strong cash flow, paying down debt, and repurchasing shares while maintaining stable Canadian rig day rates near $35,600. Its Canadian rig count held steady at 74 rigs, nearly flat year over year, showing resilience despite macro headwinds. Precision Drilling is Canada's largest land-based drilling contractor, operating a fleet of high-performance rigs across North America and the Middle East. It also offers well services and field technology solutions. While we acknowledge the potential of PDS as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: and . Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
19-07-2025
- Business
- Yahoo
Helmerich & Payne Holds Ground as Piper Sees 20% Upside Amid Rig Slowdown
Helmerich & Payne (NYSE:HP) is one of the best oil drilling stocks according to hedge funds, especially following a fresh validation from Wall Street. On July 15, Piper Sandler initiated Helmerich & Payne (NYSE:HP)'s coverage with a Neutral rating and set a $20 price target, implying about 20% upside from the ~$16 share price. That call comes amid a challenging land-drilling environment, with U.S. rig counts expected to drop from 522 to 500 and oil prices hovering below $70, yet Piper's analyst believes H&P's advanced rigs and automation tools position it well to weather the storm. Despite the Neutral rating, the deck isn't stacked against H&P. The firm just reported 47% year-over-year revenue growth last quarter, driven partly by its acquisition of KCAD and expansion overseas. Helmerich & Payne, based in Tulsa, is a leading land drilling contractor with a fleet of automated FlexRigs. It services customers across North America, the Gulf, and select international markets, focusing on performance-driven drilling tech and operational reliability. While we acknowledge the potential of HP as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: and . Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
